The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Outcomes of Ven-based regimens in CLL/SLL following intolerance or progression on covalent BTKi’s
Laura Samples, MD, University of Washington, Seattle, WA, shares the findings of a retrospective study investigating outcomes of venetoclax (Ven)-based therapy for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have progressive disease or intolerance following exposure to covalent BTK inhibitors (BTKi’s). The study raises questions about whether Ven-based fixed-duration therapy is optimal for patients who progress on BTKi’s. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
